{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "earningsTimestamp": 1683230743, "earningsTimestampStart": 1691006400, "earningsTimestampEnd": 1691438400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.11, "epsForward": -4.91, "epsCurrentYear": -4.15, "priceEpsCurrentYear": -6.178313, "sharesOutstanding": 133977000, "bookValue": 14.715, "fiftyDayAverage": 23.9378, "fiftyDayAverageChange": 1.7021999, "fiftyDayAverageChangePercent": 0.07110929, "twoHundredDayAverage": 24.706375, "twoHundredDayAverageChange": 0.93362427, "twoHundredDayAverageChangePercent": 0.0377888, "marketCap": 3435170304, "forwardPE": -5.221996, "priceToBook": 1.7424396, "currency": "USD", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "regularMarketChangePercent": 3.847707, "regularMarketPrice": 25.64, "firstTradeDateMilliseconds": 1570800600000, "priceHint": 2, "exchange": "NMS", "shortName": "Vir Biotechnology, Inc.", "longName": "Vir Biotechnology, Inc.", "messageBoardId": "finmb_419881198", "regularMarketChange": 0.94999886, "regularMarketTime": 1684180805, "regularMarketDayHigh": 25.93, "regularMarketDayRange": "24.6 - 25.93", "regularMarketDayLow": 24.6, "regularMarketVolume": 1254889, "regularMarketPreviousClose": 24.69, "bid": 0.0, "ask": 0.0, "bidSize": 8, "askSize": 8, "fullExchangeName": "NasdaqGS", "financialCurrency": "USD", "regularMarketOpen": 24.74, "averageDailyVolume3Month": 1038431, "averageDailyVolume10Day": 891400, "fiftyTwoWeekLowChange": 7.59, "fiftyTwoWeekLowChangePercent": 0.42049864, "fiftyTwoWeekRange": "18.05 - 31.78", "fiftyTwoWeekHighChange": -6.1400013, "fiftyTwoWeekHighChangePercent": -0.19320332, "fiftyTwoWeekLow": 18.05, "fiftyTwoWeekHigh": 31.78, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.9 - Buy", "tradeable": false, "cryptoTradeable": false, "displayName": "Vir Biotechnology", "symbol": "VIR"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "499 Illinois Street", "address2": "Suite 500", "city": "San Francisco", "state": "CA", "zip": "94158", "country": "United States", "phone": "415 906 4324", "website": "https://www.vir.bio", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.", "fullTimeEmployees": 576, "companyOfficers": [{"maxAge": 1, "name": "Ms. Johanna  Friedl-Naderer", "age": 54, "title": "Exec. VP & COO", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 1923699, "fmt": "1.92M", "longFmt": "1,923,699"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ann M. Hanly Ph.D.", "age": 52, "title": "Exec. VP & Chief Technology Officer", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 842232, "fmt": "842.23k", "longFmt": "842,232"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. George A. Scangos Ph.D.", "age": 74, "title": "Advisor & Director", "yearBorn": 1948, "fiscalYear": 2022, "totalPay": {"raw": 946283, "fmt": "946.28k", "longFmt": "946,283"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 11321978, "fmt": "11.32M", "longFmt": "11,321,978"}}, {"maxAge": 1, "name": "Dr. Phillip  Pang M.D., Ph.D.", "age": 47, "title": "Exec. VP, Chief Medical Officer & Interim Head of Research", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": {"raw": 837380, "fmt": "837.38k", "longFmt": "837,380"}, "exercisedValue": {"raw": 38475, "fmt": "38.48k", "longFmt": "38,475"}, "unexercisedValue": {"raw": 3344398, "fmt": "3.34M", "longFmt": "3,344,398"}}, {"maxAge": 1, "name": "Dr. Marianne  De Backer M.B.A., M.Sc., Ph.D.", "age": 53, "title": "CEO & Director", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Klaus  Frueh Ph.D.", "age": 62, "title": "Co-Founder & Scientific Advisor", "yearBorn": 1960, "fiscalYear": 2019, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Lawrence  Corey M.D.", "age": 75, "title": "Co-Founder & Scientific Advisor", "yearBorn": 1947, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Louis J. Picker M.D.", "title": "Co-Founder & Scientific Advisor", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Sung H. Lee", "age": 52, "title": "Exec. VP, CFO & Sec.", "yearBorn": 1970, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Steven J. Rice", "age": 62, "title": "Exec. VP & Chief Admin. Officer", "yearBorn": 1960, "fiscalYear": 2020, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 5, "boardRisk": 4, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 6, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}